Altimmune, Inc.
ALTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAltimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. The company carries a $665.3M market cap, placing it firmly in the small-cap category. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Market Cap
$665.3M
Beta
0.18
P/E (TTM)
—
P/E (Fwd)
-5.12
EPS (TTM)
$-0.76
EPS (Fwd)
$-0.67
ROE
-28.9%
ROA
-17.2%
Cash
$326.3M
Total Debt
$36.0M
Free CF
-$48.8M
52W Change
-9.5%
Annual Financials
Cash vs Debt
Where ALT stands vs its 150-day and 200-day moving averages
As of the August 24, 2026 close, ALT finished 9.33% below its 150-day moving average ($3.43) and 15.72% below its 200-day moving average ($3.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALT overbought or oversold?
At the August 24, 2026 close, ALT's RSI(14) was 55.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $326.3M in cash comfortably exceeding the $36.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$48.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -28.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from -$68K (2022) to $41K (2025), reflecting a 160% increase over the period.
ALT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ALT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ALT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.